- In September 2024, Merck Animal Health announced the expansion of its newly USDA-approved NOBIVAC NXT vaccine platform to include a top-tier solution for protecting cats against feline leukemia virus (FeLV), one of the most prevalent infectious diseases in felines. The vaccine is expected to be available at veterinary clinics and hospitals across the country this fall. NOBIVAC NXT FeLV is the first and only vaccine for feline leukemia virus developed using Merck Animal Health’s RNA-particle technology platform, designed to provide enhanced protection.
- In June 2024, Merck Animal Health announced the launch and availability of the NOBIVAC NXT Rabies portfolio in Canada, which includes NOBIVAC NXT Feline-3 Rabies and NOBIVAC NXT Canine-3 Rabies. This release is part of the company’s ongoing commitment to rabies prevention. The NOBIVAC NXT rabies portfolio is the first-ever line of vaccines that utilizes advanced RNA-particle technology to protect cats and dogs from rabies.
- In February 2024, the University of Pennsylvania School of Veterinary Medicine (Penn Vet) unveiled the launch of its mRNA Research Initiative. This initiative aims to accelerate the development of mRNA-based veterinary vaccines and host-directed therapies. Not only will it make a significant contribution to mRNA research, but it will also help apply the mRNA platform to create innovative veterinary vaccine solutions.
- In July 2023, Invetx announced the successful completion of the development of its species-specific, half-life extension technology for dogs and cats, resulting in a longer duration of activity for the company's veterinary monoclonal antibodies. This innovative technology allows the company to enhance antibody treatment options for chronic and severe diseases in pets. Invetx has been granted four U.S. patents for its half-life extension technology and has additional patents pending in the U.S., Europe, and other regions.
- In September 2021, Invetx announced the launch of a clinical field study in dogs aimed at an undisclosed chronic condition, using IVX-01, its proprietary, novel, fully canine, high-affinity, and half-life extended monoclonal antibody (mAb).
